University of Verona, Urology Department, Verona, Italy.
Bolzano General Hospital, Bolzano, Italy.
Eur J Surg Oncol. 2019 Mar;45(3):477-481. doi: 10.1016/j.ejso.2018.10.061. Epub 2018 Oct 21.
Women undergoing radical cystectomy (RC) followed by urinary diversion (UD) for bladder cancer experience a substantial reduction in health-related quality of life (HRQOL). At present, studies comparing long-term QOL outcomes for different UD methods, needed to inform evidence-based choices of bladder reconstruction for female patients, are sparse. Our objective was to compare two common UD methods in terms of their HRQOL outcomes in women.
We retrospectively analysed HRQOL in 73 consecutive female bladder cancer patients having undergone orthotopic ileal neobladder (IONB, N = 24) or ileal conduit (IC, N = 49) following RC between 2007 and 2013 in six Italian academic urological centres. Patients had no evidence of tumour recurrence and were actively followed up. Validated Italian versions of the European Organisation for Research and Treatment of Cancer (EORTC) generic (QLQ-C30) and bladder-cancer-specific (QLQ-BLM30) questionnaires were used to evaluate HRQOL.
Patients in the IONB group were significantly younger than those in the IC group (median age: 67 and 73 years, respectively, p = 0.02). Barring that, the two groups did not present statistically significant differences in median length of follow-up (43 vs 54 months), pathological stage, grading of the neoplasm, or adjuvant chemo - or radiotherapy. No significant differences in QOL were found between the groups, with the exception of financial difficulties, affecting IONB patients significantly more than IC patients (mean score on a scale of 0-100: 33.3 ± 29.5 vs 18.4 ± 19.3, respectively; p = 0.05).
Financial difficulties was the only HRQOL item to differ between the two UD groups.
接受根治性膀胱切除术(RC)和尿路改道(UD)治疗膀胱癌的女性患者,其健康相关生活质量(HRQOL)会显著降低。目前,对于不同 UD 方法的长期 QOL 结果比较研究,对于为女性患者提供膀胱重建的循证选择至关重要,但此类研究却很匮乏。我们的目的是比较两种常见的 UD 方法在女性患者中的 HRQOL 结果。
我们回顾性分析了 2007 年至 2013 年期间,在意大利 6 个学术泌尿外科中心接受 RC 后行原位回肠代膀胱(IONB,N=24)或回肠造口术(IC,N=49)的 73 例连续女性膀胱癌患者的 HRQOL。所有患者均无肿瘤复发证据且正在积极随访中。采用经过验证的欧洲癌症研究与治疗组织(EORTC)通用问卷(QLQ-C30)和膀胱癌特异性问卷(QLQ-BLM30)的意大利语版本评估 HRQOL。
IONB 组患者的年龄显著低于 IC 组(中位年龄:67 岁和 73 岁,p=0.02)。除此之外,两组患者在中位随访时间(43 个月与 54 个月)、病理分期、肿瘤分级或辅助化疗和放疗方面均无统计学显著差异。两组患者的 QOL 无显著差异,但在财务困难方面,IONB 组患者明显多于 IC 组(0-100 评分量表上的平均得分:33.3±29.5 与 18.4±19.3,分别;p=0.05)。
财务困难是两种 UD 组之间唯一存在差异的 HRQOL 项目。